Abstract
Lymphoid-tyrosine phosphatase (Lyp), encoded by the PTPN22 gene, is a member of the protein tyrosine phosphatase family enzymes. Human genetics studies have shown that a single-nucleotide polymorphism in PTPN22 is often mutated in patients suffering from autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosis. Because of its critical role in the regulation of T-cell Receptor (TCR) signaling pathways, Lyp recently emerged as a candidate target for therapy of autoimmune diseases. Herein, we review the structure and splice isoforms of Lyp, the biochemistry of the disease-predisposing allele, discuss the function of the phosphatase in TCR signaling and the association with human autoimmune diseases. Especially, we summarized recent progress in the development of Lyp inhibitors, intending to provide a basis for the Lyp-based treatment of autoimmunity. Moreover, the emphasis and direction for future study of Lyp in autoimmune diseases were prospected.
Keywords: Autoimmune diseases, lymphoid-tyrosine phosphatase, Lyp, PTPs, inhibitor.
Current Drug Targets
Title:Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Volume: 15 Issue: 3
Author(s): Jintong Du, Yu Qiao, Lele Sun and Xiuwen Wang
Affiliation:
Keywords: Autoimmune diseases, lymphoid-tyrosine phosphatase, Lyp, PTPs, inhibitor.
Abstract: Lymphoid-tyrosine phosphatase (Lyp), encoded by the PTPN22 gene, is a member of the protein tyrosine phosphatase family enzymes. Human genetics studies have shown that a single-nucleotide polymorphism in PTPN22 is often mutated in patients suffering from autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosis. Because of its critical role in the regulation of T-cell Receptor (TCR) signaling pathways, Lyp recently emerged as a candidate target for therapy of autoimmune diseases. Herein, we review the structure and splice isoforms of Lyp, the biochemistry of the disease-predisposing allele, discuss the function of the phosphatase in TCR signaling and the association with human autoimmune diseases. Especially, we summarized recent progress in the development of Lyp inhibitors, intending to provide a basis for the Lyp-based treatment of autoimmunity. Moreover, the emphasis and direction for future study of Lyp in autoimmune diseases were prospected.
Export Options
About this article
Cite this article as:
Du Jintong, Qiao Yu, Sun Lele and Wang Xiuwen, Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases, Current Drug Targets 2014; 15 (3) . https://dx.doi.org/10.2174/13894501113146660236
DOI https://dx.doi.org/10.2174/13894501113146660236 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review
Current Drug Targets Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review
Current Medicinal Chemistry Taking Advantage of Viral Immune Evasion: Virus-Derived Proteins Represent Novel Biopharmaceuticals
Current Medicinal Chemistry Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Oxidative Stress, Histone Deacetylase and Corticosteroid Resistance in Severe Asthma and COPD
Current Respiratory Medicine Reviews Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Structure-based Design of Mimetics for Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)
Current Pharmaceutical Design Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design Emerging Cytokines in Allergic Airway Inflammation: A Genetic Update
Current Immunology Reviews (Discontinued) Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Novel MK2 Inhibitors by Fragment Screening
Combinatorial Chemistry & High Throughput Screening Plant-based Anti-inflammatory Agents: Progress From Africa and China
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design